Do you want to read an article? Please log in or register.
Impact of patient selection on real-world outcomes by using the EMBRACE-II treatment protocol in locally advanced cervical cancer
Gynecologic Cancer
Related content
SABCS 2024
Breast Cancer
Advancing Breast Cancer Treatment with Elacestrant
Breast Cancer
Optimizing treatment sequence for inoperable locally advanced breast cancer: Long-term outcomes of surgery first versus neoadjuvant chemotherapy in a real-world setting
Int J Cancer
Liu B, Song Y, Xu Y, Sun Q, Zhou Y, Lin Y
doi: 10.1002/ijc.35140
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Front Oncol
Justeau G, Chouaid C, Debieuvre D, Audigier-Valette C, Quantin X, Léna H, Bosquet L, Girard N, Schoemaker MJ, Mella M, Pinto Correia B, Rault C, Daumont MJ, Penrod JR, Lee A, Pérol M
doi: 10.3389/fonc.2025.1526931
Gastrointestinal Cancer
Considerations to forgo systemic treatment in patients with advanced esophageal or gastric cancer: A real-world evidence study
Int J Cancer
Slotman E, Pape M, van Laarhoven HWM, Pouw RE, van der Linden YM, Verhoeven RHA, Siesling S, Fransen HP, Raijmakers NJH
doi: 10.1002/ijc.35314
Lymphoma
Real-World Direct Comparison Shows Superiority of Axi-Cel over Liso-Cel in Patients with R/R LBCL
Gastrointestinal Cancer
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real-life worldwide population
Int J Cancer
Prinzi FL, Salani F, Camera S, Rizzato MD, Saborowski A, Antonuzzo L, Rossari F, Satake T, Peeters F, Pressiani T, Lucchetti J, Kim JW, Abidoye O, Rapposelli IG, Gallio C, Tamberi S, Finkelmeier F, Giordano G, Chiara P, Chon HJ, Braconi C, Qaisar A, Pastorino A, Castet F, Tamburini E, Yoo C, Parisi A, Diana A, Scartozzi M, Prager GW, Avallone A, Schirripa M, Kim IH, Perkhofer L, Oneda E, Verrico M, Couto N, Adeva J, Chan SL, Spinelli GP, Personeni N, Garajova I, Rodriquenz MG, Leo S, Alvim CM, Roque R, Polito MG, Di Giacomo E, Farinea G, Bartalini L, Grelli G, De Rosa A, Lavacchi D, Ikeda M, Dekervel J, Niger M, Balsano R, Tonini G, Kang M, Tesini G, Boccaccino A, Himmelsbach V, Landriscina M, Djaballah SA, Bekaii-Saab T, Fornaro L, Masi G, Vogel A, Lonardi S, Rimini M, Rimassa L, Casadei-Gardini A
doi: 10.1002/ijc.70009
Further Publications
Avelumab as second-line or later treatment in patients with metastatic Merkel cell carcinoma: Analysis of real-world outcomes in France using the CARADERM database linked to the French national healthcare database
Eur J Cancer
Mortier L, Blom A, van Hille B, Samimi M, Luciani L, Cahuzac C, Robert C, Quereux G, Maubec E, Miotti H, Maillard C, Aubin F, Lenormand C, Solbes MN, Joly P, Kachaner I, Lebbé C, Dutriaux C, Saiag P
doi: 10.1016/j.ejca.2024.114261
Lung, Respiratory and Thoracic Cancer
Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE study
Lung Cancer
Wheatley-Price P, Navani V, Pabani A, Routy B, Snow S, Denault MH, Kim Y, Syed I, Devost N, Hui D, Qadeer RA, Arora P, Velummailum R, Springford A, McKibbon C, Ho C
doi: 10.1016/j.lungcan.2025.108583
Lung, Respiratory and Thoracic Cancer
Real-world treatment and outcomes for EGFR WT advanced/metastatic non-squamous non-small cell lung cancer: pooled analysis from project LUMINATE-101
Oncologist
Girard N, Xu Q, Camidge DR, Baijal S, Ng S, Kamalakar R, Ratajczak C, Alhasani H, Crawford S, Karve S, Lu S
doi: 10.1093/oncolo/oyaf029